AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis

Relaxin reverses inflammatory and immune signals in aged hearts

(2018) Brian Martin et al.   PLoS One

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study

(2017) John R. Teerlink et al.   EUROPEAN JOURNAL OF HEART FAILURE

Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury

(2017) Abdelrahman Y. Fouda et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

ML290 is a biased allosteric agonist at the relaxin receptor RXFP1

(2017) Martina Kocan et al.   Scientific Reports

Anti-fibrotic Potential of AT2 Receptor Agonists

(2017) Yan Wang et al.   Frontiers in Pharmacology

The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis

(2016) Bryna S. M. Chow et al.   DIABETOLOGIA

G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention

(2016) Kirk P. Conrad   HUMAN REPRODUCTION UPDATE

Antifibrotic Actions of Serelaxin – New Roles for an Old Player

(2016) Chrishan S. Samuel et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1

(2016) Mohammed Akhter Hossain et al.   Chemical Science

The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate

(2016) Chao Wang et al.   Frontiers in Pharmacology

Basic Pharmacological and Structural Evidence for Class A G-Protein-Coupled Receptor Heteromerization

(2016) Rafael Franco et al.   Frontiers in Pharmacology

Relative affinity of angiotensin peptides and novel ligands at AT1and AT2receptors

(2015) Sanja Bosnyak et al.   CLINICAL SCIENCE

Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins

(2014) M Sarwar et al.   BRITISH JOURNAL OF PHARMACOLOGY

Diverse Regulation of Cardiac Expression of Relaxin Receptor by α1- and β1-Adrenoceptors

(2014) Xiao-Lei Moore et al.   CARDIOVASCULAR DRUGS AND THERAPY

Therapeutic Effects of Serelaxin in Acute Heart Failure

(2014) Xiao-Jun Du et al.   CIRCULATION JOURNAL

Serelaxin Is a More Efficacious Antifibrotic Than Enalapril in an Experimental Model of Heart Disease

(2014) Chrishan S. Samuel et al.   HYPERTENSION

Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis

(2014) Bryna S. Man Chow et al.   KIDNEY INTERNATIONAL

The pathogenesis of cardiac fibrosis

(2013) Ping Kong et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Relaxin Family Peptides and Their Receptors

(2013) R. A. D. Bathgate et al.   PHYSIOLOGICAL REVIEWS

Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression

(2012) Hong Yu et al.   GENE

Angiotensin II AT2 receptor decreases AT1 receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar–Kyoto rats

(2012) Jian Yang et al.   JOURNAL OF HYPERTENSION

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

(2012) John R Teerlink et al.   LANCET

Mechanisms of fibrosis: therapeutic translation for fibrotic disease

(2012) Thomas A Wynn et al.   NATURE MEDICINE

Relaxin Signals through a RXFP1-pERK-nNOS-NO-cGMP-Dependent Pathway to Up-Regulate Matrix Metalloproteinases: The Additional Involvement of iNOS

(2012) Bryna Suet Man Chow et al.   PLoS One

Influence of Angiotensin II Subtype 2 Receptor (AT2R) Antagonist, PD123319, on Cardiovascular Remodelling of Aged Spontaneously Hypertensive Rats during Chronic Angiotensin II Subtype 1 Receptor (AT1R) Blockade

(2012) Emma S. Jones et al.   International Journal of Hypertension

Relaxin Regulates Myofibroblast Contractility and Protects against Lung Fibrosis

(2011) Xiangwei Huang et al.   AMERICAN JOURNAL OF PATHOLOGY

Heteromerization of angiotensin receptors changes trafficking and arrestin recruitment profiles

(2011) Enzo R. Porrello et al.   CELLULAR SIGNALLING

Angiotensin Type 2 Receptor Agonist Compound 21 Reduces Vascular Injury and Myocardial Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats

(2011) Asia Rehman et al.   HYPERTENSION

Postpartum Assessment of the Renin Angiotensin System in Women with Previous Severe, Early-Onset Preeclampsia

(2011) Michelle A. Hladunewich et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Renal protection with angiotensin receptor blockers: where do we stand

(2011) Roland E. Schmieder et al.   JOURNAL OF NEPHROLOGY

Antifibrotic Properties of Relaxin:In VivoMechanism of Action in Experimental Renal Tubulointerstitial Fibrosis

(2010) Tim D. Hewitson et al.   ENDOCRINOLOGY

The Positive Inotropic Effect of Relaxin-2 in Human Atrial Myocardium is Preserved in End-Stage Heart Failure: Role of Gi-Phosphoinositide-3 Kinase Signaling

(2010) Thomas Dschietzig et al.   JOURNAL OF CARDIAC FAILURE

Relaxin inhibits early steps in vascular inflammation

(2010) Anna Brecht et al.   REGULATORY PEPTIDES

The chemically synthesized human relaxin-2 analog, B-R13/17K H2, is an RXFP1 antagonist

(2009) Mohammed Akhter Hossain et al.   AMINO ACIDS

Dimerization and Negative Cooperativity in the Relaxin Family Peptide Receptors

(2009) Angela Manegold Svendsen et al.   Annals of the New York Academy of Sciences

Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy

(2009) Robert L. Chevalier et al.   KIDNEY INTERNATIONAL

Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice

(2009) KEISHI HIGASHI et al.   NEPHROLOGY

Relaxin and its role in the development and treatment of fibrosis

(2009) Robert G. Bennett   Translational Research

Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2

(2008) Ishanee Mookerjee et al.   FASEB JOURNAL

Enhanced Angiotensin II Type 2 Receptor Mechanisms Mediate Decreases in Arterial Pressure Attributable to Chronic Low-Dose Angiotensin II in Female Rats

(2008) Amanda K. Sampson et al.   HYPERTENSION

AT2 receptors: Functional relevance in cardiovascular disease

(2008) Emma S. Jones et al.   PHARMACOLOGY & THERAPEUTICS

Endogenous Relaxin Does Not Affect Chronic Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis

(2007) Qi Xu et al.   ENDOCRINOLOGY

Relaxin induces mast cell inhibition and reduces ventricular arrhythmias in a swine model of acute myocardial infarction

(2007) Silvia Nistri et al.   PHARMACOLOGICAL RESEARCH